Blood Pressure Management in Renal Failure

First-Line Therapy

The American College of Cardiology recommends ACE inhibitors or ARBs as first-line antihypertensive agents for patients with renal impairment, particularly when proteinuria or albuminuria is present, and should be uptitrated to maximally tolerated doses despite modest increases in creatinine 1
ACE inhibitors and ARBs are strongly recommended as initial therapy for hypertensive patients with chronic kidney disease (CKD), especially those with albuminuria, providing both blood pressure control and renoprotective effects 1

For ramipril, dose adaptation is required if CrCl <30 mL/min, with an initial dose of 1.25 mg daily and a maximum dose of 5 mg/day 3
For patients with proteinuric glomerular disease, uptitrate ACEi or ARB to maximally tolerated dose even without hypertension 2

Check serum creatinine and potassium within 2-4 weeks of initiating or increasing RAS inhibitor dose to detect hyperkalemia and acute kidney injury early 1
Continue ACEi/ARB if creatinine rises ≤30% within 4 weeks of initiation or dose increase, as this modest rise reflects hemodynamic changes and does not indicate harm 1, 2

For inadequate blood pressure control, add dihydropyridine calcium channel blocker (CCB) or thiazide/thiazide-like diuretic as second-line therapy 1
For resistant hypertension, add low-dose spironolactone with close monitoring of potassium and renal function, especially if eGFR <45 mL/min 1

Loop diuretics are required when GFR <30 mL/min or serum creatinine >2.0 mg/dL, as thiazides become ineffective 2
Use twice-daily dosing of loop diuretics over once-daily, and increase dose until clinically significant diuresis or maximum effective dose is reached 2

For kidney transplant recipients, start with dihydropyridine CCB or ARB as first-line therapy 1
For black patients, initial therapy should include diuretic or CCB, alone or combined with RAS inhibitor 1

Target systolic BP <120 mmHg when tolerated in most CKD patients, with systolic BP of 130-139 mmHg acceptable for diabetic or non-diabetic CKD 1

Never combine ACEi + ARB + direct renin inhibitor, as this triple combination increases adverse events without benefit 1
RAS inhibitors are contraindicated in pregnancy 1

Do not stop ACEi/ARB for modest creatinine increases, up to 30% rise is acceptable and expected 1, 2
Avoid NSAIDs, potassium supplements, and salt substitutes while on RAS inhibitors 4

Restrict dietary sodium to <2.0 g/day (<90 mmol/day) in all patients with glomerular disease and edema, enhancing diuretic efficacy and blood pressure control 2